Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 6 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q3 2023
Institutional positions in Inhibrx Biosciences, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 111
- +4 vs. Q2 2023
- Shares held
- 39.0M
- +3.00M (+8.3%) vs. Q2 2023
- Total value
- $716.1M
- −$219.0M (−23.4%) vs. Q2 2023
- New holders
- 13
- 42 more added
- Sold out
- 9
- 36 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 162 | $1.36B |
| Q1 2026 | 135 | $854.6M |
| Q4 2025 | 138 | $1.01B |
| Q3 2025 | 102 | $353.6M |
| Q2 2025 | 89 | $148.9M |
| Q1 2025 | 92 | $151.0M |
| Q4 2024 | 101 | $171.9M |
| Q3 2024 | 96 | $139.3M |
| Q2 2024 | 88 | $137.9M |
| Q1 2024 | 126 | $1.34B |
| Q4 2023 | 126 | $1.54B |
| Q3 2023 | 111 | $716.1M |
| Q2 2023 | 107 | $935.2M |
| Q1 2023 | 108 | $691.6M |
| Q4 2022 | 116 | $886.0M |
| Q3 2022 | 102 | $512.2M |
| Q2 2022 | 100 | $297.3M |
| Q1 2022 | 99 | $548.0M |
| Q4 2021 | 101 | $1.01B |
| Q3 2021 | 66 | $681.6M |
| Q2 2021 | 61 | $538.8M |
| Q1 2021 | 55 | $326.3M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Inhibrx Biosciences, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Loomis Sayles & Co L P | 1,116,484 | $20.5M | 0.04% | −34,847−3.0% | Reduced |
| Capital Research Global Investors | 1,221,721 | $22.4M | 0.01% | −530,192−30.3% | Reduced |
| FMR LLC | 1,517,595 | $27.8M | 0.00% | −254,137−14.3% | Reduced |
| Woodline Partners LP | 1,524,915 | $28.0M | 0.33% | 00.0% | Unchanged |
| State Street Corp | 1,616,771 | $29.7M | 0.00% | −200,645−11.0% | Reduced |
| TCG Crossover Management, LLC | 1,750,387 | $32.1M | 4.73% | +1,750,387 | New |
| Vanguard Group Inc | 1,789,811 | $32.8M | 0.00% | +18,271+1.0% | Added |
| BlackRock Inc. | 2,539,773 | $46.6M | 0.00% | −6,830−0.3% | Reduced |
| Perceptive Advisors LLC | 4,256,104 | $78.1M | 2.63% | +631,922+17.4% | Added |
| Ra Capital Management, L.P. | 4,724,207 | $86.7M | 1.71% | +870,340+22.6% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 7,150,826 | $131.2M | 0.53% | +511,627+7.7% | Added |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −319,500−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −92,300−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −45,000−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −35,497−100.0% | Sold out |
| Bamco Inc | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Tri Locum Partners LP | 0 | $0 | 0.00% | −15,268−100.0% | Sold out |
| State Board of Administration of Florida Retirement System | 0 | $0 | 0.00% | −9,748−100.0% | Sold out |
| Connacht Asset Management LP | 0 | $0 | 0.00% | −9,173−100.0% | Sold out |
| Harbor Capital Advisors, Inc. | 0 | $0 | 0.00% | −917−100.0% | Sold out |